These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 11862425

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JH.
    Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
    [Abstract] [Full Text] [Related]

  • 6. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
    Shin BS, Kim HJ, Hong SH, Lee JB, Hwang SW, Lee MH, Yoo SD.
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):87-94. PubMed ID: 18941747
    [Abstract] [Full Text] [Related]

  • 7. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J.
    Cancer Res; 1999 Apr 01; 59(7):1454-7. PubMed ID: 10197613
    [Abstract] [Full Text] [Related]

  • 8. Measurement of fraction unbound paclitaxel in human plasma.
    Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A.
    Drug Metab Dispos; 2000 Oct 01; 28(10):1141-5. PubMed ID: 10997930
    [Abstract] [Full Text] [Related]

  • 9. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O.
    Clin Cancer Res; 2000 Nov 01; 6(11):4416-21. PubMed ID: 11106262
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
    van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A.
    Cancer Chemother Pharmacol; 2001 Apr 01; 47(4):309-18. PubMed ID: 11345647
    [Abstract] [Full Text] [Related]

  • 11. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel.
    Chen D, Song D, Wientjes MG, Au JL.
    Clin Cancer Res; 2003 Jan 01; 9(1):363-9. PubMed ID: 12538489
    [Abstract] [Full Text] [Related]

  • 12. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
    Decorti G, Bartoli Klugmann F, Candussio L, Baldini L.
    Anticancer Res; 1996 Jan 01; 16(1):317-20. PubMed ID: 8615628
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
    Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, Ding Q, Yuan S, Shen Z, Ping Q, Zhou H.
    Biomaterials; 2008 Mar 01; 29(9):1233-41. PubMed ID: 18093646
    [Abstract] [Full Text] [Related]

  • 14. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 15. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
    Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A.
    Drug Metab Dispos; 1999 Nov 01; 27(11):1300-5. PubMed ID: 10534315
    [Abstract] [Full Text] [Related]

  • 16. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Jul 01; 50(1):16-24. PubMed ID: 12111107
    [Abstract] [Full Text] [Related]

  • 17. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):445-53. PubMed ID: 12451470
    [Abstract] [Full Text] [Related]

  • 18. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
    Danhier F, Magotteaux N, Ucakar B, Lecouturier N, Brewster M, Préat V.
    Eur J Pharm Biopharm; 2009 Oct 01; 73(2):230-8. PubMed ID: 19577643
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
    Jamois C, Comets E, Mentré F, Marion S, Farinotti R, Bonhomme-Faivre L.
    Cancer Chemother Pharmacol; 2005 Jan 01; 55(1):61-71. PubMed ID: 15378273
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of cremophor EL with bolus doxorubicin.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM.
    Clin Cancer Res; 1998 Oct 01; 4(10):2321-9. PubMed ID: 9796961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.